ALTEPLASE

Search structure
Trade Names:
Synonyms:
Status: Approved (1996)
Entry Type: Enzyme
Molecule Category: UNKNOWN
ATC: B01AD02
UNII: 1RXS4UE564

Pharmacology

Action Mechanism of Action Reference
EXOGENOUS PROTEIN Tissue-type plasminogen activator exogenous protein

Indications

Mesh Heading Maximum Phase Mesh ID Reference
Thrombosis 4 D013927 ClinicalTrials
Stroke 4 D020521 ClinicalTrials
Myocardial Infarction 4 D009203 ClinicalTrials
Pulmonary Embolism 4 D011655 ClinicalTrials
Abscess 3 D000038 ClinicalTrials
Empyema 3 D004653 ClinicalTrials
Cerebral Hemorrhage 3 D002543 ClinicalTrials
Hemorrhage 3 D006470 ClinicalTrials
Subarachnoid Hemorrhage 3 D013345 ClinicalTrials
Retinal Artery Occlusion 3 D015356 ClinicalTrials
Empyema, Pleural 3 D016724 ClinicalTrials
Myocardial Ischemia 3 D017202 ClinicalTrials
Angina, Stable 3 D060050 ClinicalTrials
Respiratory Distress Syndrome 3 D012128 ClinicalTrials
Ischemic Stroke 3 D000083242 ClinicalTrials
Cerebral Infarction 3 D002544 ClinicalTrials
Brain Ischemia 3 D002545 ClinicalTrials
Cardiovascular Diseases 3 D002318 ClinicalTrials
Coronary Disease 3 D003327 ClinicalTrials
Retinal Hemorrhage 2 D012166 ClinicalTrials
Neoplasms 2 D009369 ClinicalTrials
Macular Degeneration 2 D008268 ClinicalTrials
Severe Acute Respiratory Syndrome 2 D045169 ClinicalTrials
Neoplasms 2 D009369 ClinicalTrials
Arterial Occlusive Diseases 2 D001157 ClinicalTrials
Respiratory Insufficiency 2 D012131 ClinicalTrials
Severe Acute Respiratory Syndrome 2 D045169 ClinicalTrials
Venous Thrombosis 2 D020246 ClinicalTrials
Nervous System Diseases 2 D009422 ClinicalTrials
Abdominal Abscess 2 D018784 ClinicalTrials
Urinary Retention 2 D016055 ClinicalTrials
Bronchitis 2 D001991 ClinicalTrials
Infections 2 D007239 ClinicalTrials
Retinal Vein Occlusion 1 D012170 ClinicalTrials
Hematologic Neoplasms 1 D019337 ClinicalTrials
Thrombophlebitis 1 D013924 ClinicalTrials

Adverse Reactions

SOC By Demographic Distribution
System Organ Classification (SOC)
Relative Frequency (%)
Vascular disorders
21.23
Nervous system disorders
15.25
General disorders and administration site conditions
13.16
Cardiac disorders
9.72
Respiratory, thoracic and mediastinal disorders
7.79
Injury, poisoning and procedural complications
7.4
Gastrointestinal disorders
4.28
Skin and subcutaneous tissue disorders
3.94
Immune system disorders
2.92
Investigations
2.72

Cross References

Resources Reference
CAS NUMBER 105857-23-6
ChEMBL CHEMBL1201593
FDA SRS 1RXS4UE564
CONTENTS